The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Blockade of Interleukin-12 Function by Protein Vaccination Attenuates Atherosclerosis
Abstract
Background— Interleukin-12 (IL-12) has been identified as a key inducer of a type 1 T-helper cell cytokine pattern, which is thought to contribute to the development of atherosclerosis. We sought to study the role of IL-12 in atherosclerosis by inhibition of IL-12 using a newly developed vaccination technique that fully blocks the action of IL-12. Methods and Results— LDL receptor–deficient (LDLr −/− ) mice were vaccinated against IL-12 by 5 intramuscular injections of IL-12–PADRE complex in combination with adjuvant oil-in-water emulsion (low dose)/MPL/QS21 every 2 weeks. Two weeks thereafter, atherogenesis was initiated in the carotid artery by perivascular placement of silicone elastomer collars. IL-12 vaccination resulted in the induction of anti–IL-12 antibodies that functionally blocked the action of IL-12 as determined in an IL-12 bioassay. Blockade of IL-12 by vaccination of LDLr −/− mice resulted in significantly reduced (68.5%; P <0.01) atherogenesis compared with control mice without a change in serum cholesterol levels. IL-12 vaccination also resulted in a significant decrease in intima/media ratios (66.7%; P <0.01) and in the degree of stenosis (57.8%; P <0.01). On IL-12 vaccination, smooth muscle cell and collagen content in the neointima increased 2.8-fold ( P <0.01) and 4.2-fold ( P <0.01), respectively. Conclusions— Functional blockade of endogenous IL-12 by vaccination resulted in a significant 68.5% reduction in atherogenesis in LDLr −/− mice. Vaccination against IL-12 also improved plaque stability, from which we conclude that the blockade of IL-12 by vaccination may be considered a promising new strategy in the treatment of atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and Atherosclerosis
Libby, P., Ridker, P. M., & Maseri, A. (2002) · Circulation · doi:10.1161/hc0902.104353 · Cited by 7,724
Cited by
The immune system in atherosclerosis
Hansson, G. K., & Hermansson, A. (2011) · Nature Immunology · doi:10.1038/ni.2001 · Cited by 2,317
Cytokines and atherosclerosis: a comprehensive review of studies in mice
Kleemann, R., Zadelaar, S., & Kooistra, T. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn120 · Cited by 606
Microanatomy of the Human Atherosclerotic Plaque by Single-Cell Transcriptomics
Depuydt, M. A. C., Prange, K. H. M., Slenders, L., Örd, T., Elbersen, D., Boltjes, A., de Jager, S. C. A., Asselbergs, F. W., de Borst, G. J., Aavik, E., et al. (2020) · Circulation Research · doi:10.1161/circresaha.120.316770 · Cited by 594
Self-citationRecent Advances on the Role of Cytokines in Atherosclerosis
Ait-Oufella, H., Taleb, S., Mallat, Z., & Tedgui, A. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.207415 · Cited by 578
The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity
Boehncke, W.-H., Boehncke, S., Tobin, A.-M., & Kirby, B. (2011) · Experimental Dermatology · doi:10.1111/j.1600-0625.2011.01261.x · Cited by 530
Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets
Ramji, D. P., & Davies, T. S. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.04.003 · Cited by 469
Inflammation and immune system interactions in atherosclerosis
Legein, B., Temmerman, L., Biessen, E. A. L., & Lutgens, E. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1289-1 · Cited by 292
Ryan, C., Leonardi, C. L., Krueger, J. G., Kimball, A. B., Strober, B. E., Gordon, K. B., Langley, R. G., de Lemos, J. A., Daoud, Y., Blankenship, D., et al. (2011) · JAMA · doi:10.1001/jama.2011.1211 · Cited by 289
Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis
Ridker, P. M. (2019) · Circulation Research · doi:10.1161/circresaha.118.313129 · Cited by 260
“In an early preclinical trial, blockade of IL-12 function through protein vaccination lead to attenuation of atherosclerosis in LDLr mice.(141) More recent murine evidence with erlotinib— a selective inhibitor of the epidermal growth factor receptor— also suggests reductions in experimental atherosclerosis.”
BackgroundAdaptive Response of T and B Cells in Atherosclerosis
Ketelhuth, D. F. J., & Hansson, G. K. (2016) · Circulation Research · doi:10.1161/circresaha.115.306427 · Cited by 270
Maes, M., Ruckoanich, P., Chang, Y. S., Mahanonda, N., & Berk, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.06.008 · Cited by 169
Targeting inflammation to reduce cardiovascular disease risk: A realistic clinical prospect?
Welsh, P., Grassia, G., Botha, S., Sattar, N., & Maffia, P. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13818 · Cited by 164
Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis
Li, B., Li, W., Li, X., & Zhou, H. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612822666161230142931 · Cited by 130
“In LDLr mice, the IL-12 antibody resulted in a significant reduction of atherosclerotic lesion size [71].”
BackgroundmiR-223 Exerts Translational Control of Proatherogenic Genes in Macrophages
Nguyen, M.-A., Hoang, H.-D., Rasheed, A., Duchez, A.-C., Wyatt, H., Cottee, M. L., Graber, T. E., Susser, L., Robichaud, S., Berber, İ., et al. (2022) · Circulation Research · doi:10.1161/circresaha.121.319120 · Cited by 74
Metadata
- Authors
- Hauer, A. D., Uyttenhove, C., de Vos, P., Stroobant, V., Renauld, J. C., van Berkel, T. J. C., van Snick, J., & Kuiper, J.
- Venue
- Circulation
- Published
- 2005-08-16
- Volume
- 112
- Issue
- 7
- Pages
- 1054-1062
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2102774054
- Cited by
- 182
- References
- 1
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.